Site Editor
Leo I. Gordon, MD, FACP
Leo I. Gordon, MD, FACP
Posted: Thursday, August 11, 2022
For physicians treating patients with follicular lymphoma in the third-line setting, treatment efficacy and improved survival attributes are considered the most important factors when selecting among treatment options, according to findings presented at the European Hematology Association (EHA) 2022 Congress (Abstract P1095). A patient’s quality of life and the cost of treatment, among other factors, were considered less important to respondents of a survey of oncologists and hematologists across Western Europe and the United States, reported P. Connor Johnson, MD, of Harvard Medical School, Boston, and colleagues.
In this study, the authors drew data from the Adelphi Follicular Lymphoma Disease-Specific Programme, a point-in-time study conducted from June 2021 to January 2022. In total, 251 physicians completed an online survey regarding self-reported demographics and the top seven treatment attributes the physicians considered when selecting third-line follicular lymphoma treatment. Of the survey group, 49% were hematologist oncologists, 41% were hematologists, and 10% were medical oncologists. More than half (52%) worked primarily at hospitals.
Among the top seven reported attributes, progression-free survival (74.1%), overall survival (70.1%), duration of response (59.8%), evidence-based efficacy overall and overall response (57.4%), and the ability to achieve a complete response (46.2%) were the most frequently cited. Long-term safety and the impact on a patient’s quality of life were reported among the top attributes 38.6% and 34.3% of the time, respectively.
In contrast, few physicians reported cost (4.8%), patient acceptability of lag time between leukapheresis and chimeric antigen receptor T-cell infusion (7.2%), patient acceptability of the frequency of administration (8.0%), less monitoring needed (8.8%), and fewer outpatient and inpatient consultations needed (5.6% and 7.6%, respectively) among their top attributes considered.
The authors noted some differences in top attributes between European and U.S.-based respondents. They included long-term safety (35.8% and 50.0%, respectively), impact on patient’s quality of life (37.8% and 20.0%, respectively), and suitability for patients aged 60 or older (10.9% and 22.0%, respectively).
Disclosure: For full disclosures of the study authors, visit ehaweb.org.
